Concepedia

Sarah W. Li

SW

Statistics

Publications

4

Citations

414

H-Index

4

Active since

2009

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Sarah W. Li is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, drug discovery, and pharmacology.

Top concepts

MedicinePharmacologyDrug DiscoveryNeuropharmacologyBiochemistryPeptide SciencePharmacotherapySmall MoleculesDrug DevelopmentAlzheimer's Disease

Publications per year

2009–2017

4

Publications

4

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 161 citations · Full text

Neurochemical Biomarkers, Peptide Science, Enzyme 1 +19

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Jack D. Scott, Duane E. DeMong, Thomas J. Greshock et al. · Journal of Medicinal Chemistry · 2017 · 140 citations · Full text

Drug Target, Pharmacotherapy, Medicinal Chemistry +16

Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction

Andrew W. Stamford, Jack D. Scott, Sarah W. Li et al. · ACS Medicinal Chemistry Letters · 2012 · 98 citations · Full text

Drug Target, Neurochemical Biomarkers, Peptide Science +22

Tetrahydroquinoline sulfonamides as vasopressin 1b receptor anatgonists

Jack D. Scott, Michael W. Miller, Sarah W. Li et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 15 citations · Full text

Medicine, Physiology, Mechanism Of Action +7

1–4 of 4